Logo
x

Search

Subscribe Now

Lannett

Lannett Entered into a Patent License Agreement with Ypsomed and HEC for Pen Injector Device in Use of Biosimilar Insulin Glargine and Insulin Aspart

Lannett Entered into a Patent License Agreement with Ypsomed and HEC for Pen Injector Device in Use of Biosimilar Insulin Glargine...

  • November 7, 2022
Lannett Reports the Completion of Patient Dosing in Pivotal Clinical Trial for Biosimilar Insulin Glargine

Lannett Reports the Completion of Patient Dosing in Pivotal Clinical Trial for Biosimilar Insulin Glargine

  • August 31, 2022
Lannett Reports Updates of Biosimilar Insulin Glargine

Lannett Reports Updates of Biosimilar Insulin Glargine

  • June 1, 2022
Insights+ Key Biosimilars Events of March 2022

Insights+ Key Biosimilars Events of March 2022

  • April 7, 2022
Lannett Reports the First Patient Dosing in the Pivotal Clinical Trial of Biosimilar Insulin Glargine

Lannett Reports the First Patient Dosing in the Pivotal Clinical Trial of Biosimilar Insulin Glargine

  • March 29, 2022
Lannett Receives the US FDA’s IND Clearance of Biosimilar Insulin Glargine

Lannett Receives the US FDA’s IND Clearance of Biosimilar Insulin Glargine

  • January 21, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.